Clinical Safety and Efficacy of Bispecific Antibody in the Treatment of Solid Tumors: A Protocol for a Systematic Review Publisher Pubmed



Nejadghaderi SA^{1, 2} ; Balibegloo M^{1, 2, 3} ; Saghazadeh A^{1, 4} ; Rezaei N^{3, 4, 5} Show Affiliations
Source: PLoS ONE Published:2022

Abstract

Background Cancers are among the most common causes of mortality and morbidity. Recently, bispecific antibodies (BsAbs) have been used for cancer treatment. The aim of this systematic review and meta-analysis will be to determine the safety and efficacy of BsAbs in the treatment of solid tumors. Methods We will search five electronic databases, PubMed, EMBASE, Scopus, Web of Science, and CENTRAL, in addition to Clinical-Trials.gov and metaRegister of controlled trials and backward and forward citation searching of included studies. Eligible studies will be controlled clinical trials evaluating safety and/or efficacy of BsAbs in adult patients with solid tumors. The primary outcomes will be the incidence of safety and efficacy measures. Title and/or abstract screening, full text reviewing, data collection, and quality assessment will be done by two reviewers. We will use The Cochrane Collaboration’s risk of bias tool 2 (RoB2) to assess the quality of included studies. If I-square heterogeneity was greater than 40%, we will implement random effect model. Subgroup analysis and meta-regression will be undertaken if applicable. The metaprop command of STATA will be used to calculate frequency of AEs. Funnel plot, Egger’s and Peter’s tests will be utilized to evaluate publication bias in case of including at least ten studies. We will use sensitivity analysis to evaluate the effects of funding sources and continuity correction on effects size. Conclusions The findings of the present study will provide information on safety and efficacy of BsAbs for physicians and researchers in the management of solid tumors. © 2022 Nejadghaderi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.